Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Bottom line: A Phase 2 trial is investigating whether psilocybin may enhance the effects of cognitive training on brain function in older adults with early signs of Alzheimer’s disease.
A Phase 2 trial is exploring whether psilocybin, the psychoactive compound in certain mushrooms, can boost the effects of cognitive training on brain function in older adults with early signs of Alzheimer’s disease.
Cognitive decline in aging is a growing concern, and combining mental exercises with psychedelic compounds could offer new hope. This trial explores whether psilocybin enhances the benefits of cognitive training in older adults.

What’s being tested
This trial investigates whether combining cognitive training with psilocybin can improve brain function in older adults with mild cognitive impairment or early-stage Alzheimer’s disease. The study aims to determine if psilocybin can amplify the effects of regular mental exercises on neuroplasticity — the brain’s ability to reorganize itself by forming new neural connections.
The design at a glance
This Phase 2 trial is currently recruiting participants and is sponsored by the National Institute on Aging (NIA). Phase 2 studies typically focus on assessing the effectiveness of an intervention and its safety in a larger group of people. Participants will undergo a series of screenings, including heart function tests, brain imaging, and cognitive assessments. They will then engage in cognitive training exercises, with some also receiving psilocybin under medical supervision. The study will evaluate changes in brain function and cognitive performance over time.
Why it matters
If successful, this trial could provide insights into how psychedelics might support cognitive health in aging populations. Alzheimer’s disease and related dementias are among the most challenging neurological conditions, with limited treatment options. Enhancing neuroplasticity through non-invasive methods like cognitive training and psilocybin could offer a novel approach to preserving mental function and slowing cognitive decline. The results may also inform future research on the therapeutic potential of psychedelics in neurodegenerative diseases.
What this does NOT mean yet
It is important to note that this trial is still in the recruitment phase and has not yet produced any results. Registration on ClinicalTrials.gov does not imply that the intervention is effective or safe; it simply means the study is planned and seeking participants. Many clinical trials fail to meet their goals or do not show significant benefits, and results can take years to be published. Until the trial is completed and the findings are peer-reviewed, no conclusions about the efficacy of psilocybin and cognitive training can be drawn.
How to follow it
You can track the progress of this trial directly through its official record on ClinicalTrials.gov. The results of the study will be posted there once they become available, providing the public with access to the findings.
Sources
https://clinicaltrials.gov/study/NCT07721467 | NCT07721467
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.